{"id":14609,"date":"2023-08-29T14:42:00","date_gmt":"2023-08-29T06:42:00","guid":{"rendered":"https:\/\/flcube.com\/?p=14609"},"modified":"2024-11-24T14:49:00","modified_gmt":"2024-11-24T06:49:00","slug":"lundbeck-a-s-reports-10-h1-2023-revenue-increase-with-record-breaking-sales","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14609","title":{"rendered":"Lundbeck A\/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales"},"content":{"rendered":"\n

Denmark-based biopharmaceutical company H. Lundbeck A\/S (OTCMKTS: HLBBF<\/a>) has released its financial report for the H1 2023 period, reporting a 10% year-on-year (YOY) increase in sales revenues in constant exchange rate terms, reaching DKK 10 billion (USD 1.45 billion) over the six-month period. CEO Deborah Dunsire celebrated the “excellent performance,” which marked a new record for H1 revenues.<\/p>\n\n\n\n

Vyepti’s Rapid Growth and Other Portfolio Highlights<\/strong>
Migraine drug Vyepti (eptinezumab) emerged as the fastest-growing product in Lundbeck’s portfolio. Launched in the US and globally from 2020 onwards, H1’23 growth reached 91% YOY, amounting to DKK 757 million (USD 110 million). Other notable growth came from major depressive disorder therapy Brintellix\/Trintellix (vortioxetine), which grew by 6% to DKK 2.156 billion (USD 313.5 million); depression and schizophrenia drug Rexulti\/Rxulti (brexpiprazole), with an 18% increase to DKK 2.135 billion (USD 310.5 million); and antipsychotic drug Abilify Maintena\/Asimtufii (aripiprazole), expanding sales by 14% YOY to DKK 1,584 million (USD 230 million).<\/p>\n\n\n\n

Rexulti’s Alzheimer’s-Related Dementia Indication and FDA Approval<\/strong>
Significantly, during H1’23, Rexulti, co-developed with partner Otsuka Pharmaceutical, was launched as a treatment for agitation associated with dementia due to Alzheimer’s disease (AADDA), a potential blockbuster indication. Rexulti is the first and only drug to receive FDA approval for this specific indication.<\/p>\n\n\n\n

Leadership Transition at Lundbeck<\/strong>
Deborah Dunsire, who has overseen a shift in Lundbeck’s portfolio towards more innovative drug development, is hosting her final financial report presentations. She is set to step down from her position as President and CEO of Lundbeck from September 1, 2023. Charl van Zyl is poised to take over the role, leaving his position as executive vice-president and head of neurology for Europe and international markets at UCB S.A. (Euronext:UCB).-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Denmark-based biopharmaceutical company H. Lundbeck A\/S (OTCMKTS: HLBBF) has released its financial report for the…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[20,27,1581,1580],"class_list":["post-14609","post","type-post","status-publish","format-standard","hentry","category-company","tag-finance","tag-finanical-reports","tag-h-lundbeck","tag-otcmkts-hlbbf"],"yoast_head":"\nLundbeck A\/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Denmark-based biopharmaceutical company H. Lundbeck A\/S (OTCMKTS: HLBBF) has released its financial report for the H1 2023 period, reporting a 10% year-on-year (YOY) increase in sales revenues in constant exchange rate terms, reaching DKK 10 billion (USD 1.45 billion) over the six-month period. CEO Deborah Dunsire celebrated the "excellent performance," which marked a new record for H1 revenues.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14609\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lundbeck A\/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14609\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-29T06:42:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-24T06:49:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14609#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14609\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lundbeck A\\\/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales\",\"datePublished\":\"2023-08-29T06:42:00+00:00\",\"dateModified\":\"2024-11-24T06:49:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14609\"},\"wordCount\":287,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finance\",\"Finanical Reports\",\"H. Lundbeck\",\"OTCMKTS: HLBBF\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14609#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14609\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14609\",\"name\":\"Lundbeck A\\\/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-29T06:42:00+00:00\",\"dateModified\":\"2024-11-24T06:49:00+00:00\",\"description\":\"Denmark-based biopharmaceutical company H. Lundbeck A\\\/S (OTCMKTS: HLBBF) has released its financial report for the H1 2023 period, reporting a 10% year-on-year (YOY) increase in sales revenues in constant exchange rate terms, reaching DKK 10 billion (USD 1.45 billion) over the six-month period. CEO Deborah Dunsire celebrated the \\\"excellent performance,\\\" which marked a new record for H1 revenues.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14609#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14609\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14609#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lundbeck A\\\/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lundbeck A\/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales - Insight, China's Pharmaceutical Industry","description":"Denmark-based biopharmaceutical company H. Lundbeck A\/S (OTCMKTS: HLBBF) has released its financial report for the H1 2023 period, reporting a 10% year-on-year (YOY) increase in sales revenues in constant exchange rate terms, reaching DKK 10 billion (USD 1.45 billion) over the six-month period. CEO Deborah Dunsire celebrated the \"excellent performance,\" which marked a new record for H1 revenues.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14609","og_locale":"en_US","og_type":"article","og_title":"Lundbeck A\/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14609","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-29T06:42:00+00:00","article_modified_time":"2024-11-24T06:49:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14609#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14609"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lundbeck A\/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales","datePublished":"2023-08-29T06:42:00+00:00","dateModified":"2024-11-24T06:49:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14609"},"wordCount":287,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finance","Finanical Reports","H. Lundbeck","OTCMKTS: HLBBF"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14609#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14609","url":"https:\/\/flcube.com\/?p=14609","name":"Lundbeck A\/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-29T06:42:00+00:00","dateModified":"2024-11-24T06:49:00+00:00","description":"Denmark-based biopharmaceutical company H. Lundbeck A\/S (OTCMKTS: HLBBF) has released its financial report for the H1 2023 period, reporting a 10% year-on-year (YOY) increase in sales revenues in constant exchange rate terms, reaching DKK 10 billion (USD 1.45 billion) over the six-month period. CEO Deborah Dunsire celebrated the \"excellent performance,\" which marked a new record for H1 revenues.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14609#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14609"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14609#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lundbeck A\/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14609"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14609\/revisions"}],"predecessor-version":[{"id":14610,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14609\/revisions\/14610"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}